当前期刊: Current Hematologic Malignancy Reports Go to current issue    加入关注   
显示样式:        排序: IF: - GO 导出
我的关注
我的收藏
您暂时未登录!
登录
  • Novel Therapies in the Treatment of Adult Acute Lymphoblastic Leukemia.
    Curr. Hematol. Malig. Rep. (IF 2.397) Pub Date : 2020-05-22
    Alexander Gavralidis,Andrew M Brunner

    PURPOSE OF REVIEW Acute lymphoblastic leukemia (ALL) is a rare hematologic malignancy. Advances in multi-agent chemotherapy have resulted in dramatic improvements in the number of pediatric cases that result in a cure; however, until recently, treatment options for older adults or patients with relapsed and refractory disease were extremely limited. This review seeks to describe in greater detail a

    更新日期:2020-05-22
  • Primary Cutaneous CD30+ Lymphoproliferative Disorders: a Comprehensive Review.
    Curr. Hematol. Malig. Rep. (IF 2.397) Pub Date : 2020-05-20
    Cosimo Di Raimondo,Vishwas Parekh,Joo Y Song,Steven T Rosen,Christiane Querfeld,Jasmine Zain,Xochiquetzal U Martinez,Farah R Abdulla

    PURPOSE OF REVIEW Primary cutaneous CD30+ T-cell lymphoproliferative disorders (CD30+ LPDs) are the second most common cutaneous lymphomas after mycosis fungoides and Sezary syndrome. They include primary cutaneous anaplastic large cell lymphoma (pcALCL), lymphomatoid papulosis (LyP), and borderline lesions. The purpose of this literature review is to consolidate the available evidence on the primary

    更新日期:2020-05-20
  • Radiogenomics and Its Role in Lymphoma.
    Curr. Hematol. Malig. Rep. (IF 2.397) Pub Date : 2020-05-20
    Saman Khan,Sohaib Naim,Rania Bilwani,Amirah Salem,David Gorlin,Ahmad Muhammad,Maryam Gul,Muhammad H Imam,Ammar Chaudhry

    PURPOSE OF REVIEW Imaging features of lymphoma vary regionally. Awareness of site-specific key imaging characteristics of lymphoma can aid in rapid staging and assist in prompt treatment. FDG PET/CT and conventional MRI are readily available diagnostic modalities with excellent sensitivity and good specificity. Diagnostic specificity can be enhanced using emerging PET radiotracers, e.g., FLT and FET

    更新日期:2020-05-20
  • Editing of Endogenous Genes in Cellular Immunotherapies.
    Curr. Hematol. Malig. Rep. (IF 2.397) Pub Date : 2020-05-15
    Theodore L Roth

    PURPOSE OF REVIEW T cell-based cellular and antibody immunotherapies have dramatically altered the landscape of cancer treatment over the past decade. Over the same time span, gene editing technologies have enabled unprecedented degrees of genetic control. RECENT FINDINGS Knock-outs of endogenous genes, especially based on electroporation of targetable nucleases such as CRISPR/Cas9, have rapidly proliferated

    更新日期:2020-05-15
  • Management of Ibrutinib Toxicities: a Practical Guide.
    Curr. Hematol. Malig. Rep. (IF 2.397) Pub Date : 2020-05-15
    Masa Lasica,Constantine S Tam

    PURPOSE OF REVIEW Ibrutinib is a first-in-class, highly potent Bruton tyrosine kinase inhibitor which has become standard of care for patients with chronic lymphocytic leukaemia and other lymphoproliferative disorders. It requires indefinite administration which places emphasis on toxicity and long-term tolerance. RECENT FINDINGS Extensive use of ibrutinib in studies and clinical practice has better

    更新日期:2020-05-15
  • Thrombocytosis and Thrombosis: Is There Really a Correlation?
    Curr. Hematol. Malig. Rep. (IF 2.397) Pub Date : 2020-05-12
    Carlos Galvez,Brady L Stein

    PURPOSE OF REVIEW Thrombocytosis is common to all myeloproliferative neoplasms (MPN), including essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis. Despite the traditionally held belief amongst many clinicians that thrombocytosis correlates with thrombosis risk, there is little evidence in the literature to support that claim. Herein we critically analyze the literature to better

    更新日期:2020-05-12
  • Updates in the Diagnosis and Management of AL Amyloidosis.
    Curr. Hematol. Malig. Rep. (IF 2.397) Pub Date : 2020-05-11
    Joselle Cook,Eli Muchtar,Rahma Warsame

    PURPOSE OF REVIEW Light chain (AL) amyloidosis is an insidious progressive disease which results in significant morbidity and inevitable mortality if not diagnosed and treated promptly. This review will highlight recent developments and summarize critical clinical points and updated practice changes for the clinician in 2020. RECENT FINDINGS Comparative analyses of staging systems, updated prognostic

    更新日期:2020-05-11
  • PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
    Curr. Hematol. Malig. Rep. (IF 2.397) Pub Date : 2020-05-11
    Wei Xie,L Jeffrey Medeiros,Shaoying Li,C Cameron Yin,Joseph D Khoury,Jie Xu

    PURPOSE OF REVIEW Programmed cell death protein-1 (PD-1) is currently the most extensively studied inhibitory checkpoint molecule. Many malignant neoplasms express the PD-1 ligands, PD-L1, and/or PD-L2, which bind to PD-1 on T cells and induce T cell "exhaustion." By doing so, the malignant cells escape from an antitumor immune response (immune evasion). Blockade of the PD-1/PD-L1 pathway releases

    更新日期:2020-05-11
  • Utilizing Real-World Evidence (RWE) to Improve Care in Chronic Lymphocytic Leukemia: Challenges and Opportunities.
    Curr. Hematol. Malig. Rep. (IF 2.397) Pub Date : 2020-05-07
    Prioty Islam,Anthony R Mato

    PURPOSE OF REVIEW This review discusses important findings from real-world evidence (RWE) studies impacting the field of chronic lymphocytic leukemia (CLL), from prognostication to long-term management and sequencing of novel agents. RECENT FINDINGS RWE data, which represents a heterogeneous cohort of patients treated at non-academic centers and off-clinical trial, demonstrate several key differences

    更新日期:2020-05-07
  • Clinical Applications of Chromosomal Microarray Testing in Myeloid Malignancies.
    Curr. Hematol. Malig. Rep. (IF 2.397) Pub Date : 2020-05-07
    Arash Ronaghy,Richard K Yang,Joseph D Khoury,Rashmi Kanagal-Shamanna

    PURPOSE OF REVIEW Knowledge of both somatic mutations and copy number aberrations are important for the understanding of cancer pathogenesis and management of myeloid neoplasms. The currently available standard of care technologies for copy number assessment such as conventional karyotype and FISH are either limited by low resolution or restriction to targeted assessment. RECENT FINDINGS Chromosomal

    <